论文部分内容阅读
目的研究血脂康对不稳定型心绞痛(UAP)患者抗炎抗氧化治疗的效果。方法采用酶联免疫吸附法(ELISA)测定61例UAP患者(UAP组)服用血脂康前后和40例冠脉造影正常者(对照组)白细胞介素-6(IL-6)及肿瘤坏死因子α(TNF-α)血浆浓度。结果UAP组血浆IL-6、TNF-α水平为(25.03±6.31)pg/L和(21.35±4.39)μg/L,与对照组(19.87±5.98)pg/L和(16.67±4.29)μg/L相比有显著性差异(P均<0.01),服用血脂康4周后UAP组血浆IL-6及TNF-α水平明显下降。结论血脂康在抑制UAP患者炎症反应、稳定动脉粥样斑块、减少急性心血管事件方面可能有一定的作用。
Objective To study the effect of Xuezhikang on anti-inflammatory and anti-oxidant treatment in patients with unstable angina pectoris (UAP). Methods The levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in 61 patients with UAP (UAP group) before and after treatment with Xuezhikang and 40 patients with coronary artery disease (control group) were measured by enzyme-linked immunosorbent assay (ELISA) (TNF-α) plasma concentration. Results The levels of IL-6 and TNF-α in the UAP group were (25.03 ± 6.31) pg / L and (21.35 ± 4.39) μg / L, respectively, significantly higher than those in the control group (19.87 ± 5.98 pg / L and 16.67 ± 4.29 μg / (P <0.01). The levels of IL-6 and TNF-α in plasma of UAP group were significantly decreased after taking Xuezhikang for 4 weeks. Conclusion Xuezhikang may play an important role in inhibiting inflammation, stabilizing atherosclerotic plaque and reducing acute cardiovascular events in UAP patients.